Substituted pyrazole compounds as CRAC modulators

1. A compound having the Formula (I):

wherein,

one of A and B is N and the other is CR 3 ;

L is selected from —C(O)NR 11 —, —NR 11 C(O)—, —CR a R b NR 11 —and —NR 11 CR a R b —;

at each occurrence, R a and R b are independently hydrogen, substituted or unsubstituted alkyl or halogen;

ring E is 5 membered non aromatic heterocyclic ring of Formula (a)

X is —NR—;

Y is —C(O)—;

R is selected from substituted or unsubstituted alkyl, haloalkyl, substituted or unsubstituted cycloalkyl, and —C(O)R 8 ;

R 1 , which may be same or different at each occurrence, is independently selected from halogen, cyano, hydroxyl, substituted or unsubstituted alkyl, haloalkyl, substituted or unsubstituted alkoxy, haloalkoxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkoxy, and —C(O)OR 9 ; or any two of adjacent R 1 groups together with the phenyl to which they are attached form substituted or unsubstituted naphthalene ring;

R 2 is selected from halogen, cyano, nitro, hydroxyl, substituted or unsubstituted alkyl, haloalkyl, substituted or unsubstituted alkoxy, haloalkoxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkoxy, —NR 6 R 7 , —NHC(O)R 8 , and —C(O)OR 9 ;

R 3 is selected from hydrogen, halogen, cyano, hydroxyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, and substituted or unsubstituted cycloalkyl;

R 6 and R 7 , which may be same or different at each occurrence, are independently selected from hydrogen, substituted or unsubstituted alkyl and substituted or unsubstituted cycloalkyl;

R 8 is substituted or unsubstituted alkyl;

R 9 is hydrogen or substituted or unsubstituted alkyl;

at each occurrence, R 11 is independently hydrogen or substituted or unsubstituted alkyl;

n is an integer ranging from 0 to 4, both inclusive; and

where the substituents on alkyl, cycloalkyl, alkoxy, cycloalkoxy, naphthalene ring are independently selected from hydroxy, halogen, carboxyl, cyano, nitro, alkyl, haloalkyl, aryl, cycloalkyl, —C(O)OR x , —C(O)NR x R y , —NR x R y , —NR x C(O)R y , —S(O) 2 NR x R y , —OR x , —SR x , and —S(O) 2 R x ; wherein each occurrence of R x , R y and R z are independently selected from hydrogen, halogen, alkyl, haloalkyl and cycloalkyl;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , having the Formula (II):

or a pharmaceutically acceptable salt thereof;

wherein ring E, R 1 , R 2 , R 3 , L and ‘n’ are as defined in claim- 1 .

3. The compound of claim 1 , having the Formula-(III):

or a pharmaceutically acceptable salt thereof;

wherein ring E, R 1 , R 2 , R 3 , L and ‘n’ are as defined in claim- 1 .

4. The compound of claim 1 , wherein ring E is (a)

wherein X and y as defined in claim- 1 , and or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein L is selected from —C(O)NR 11 —, —NR 11 C(O)—and —NR 11 CR a R b —wherein R 11 , R a and R b are independently a hydrogen or alkyl.

6. The compound of claim 1 , wherein R 1 is same or different and are independently selected from halogen, cyano, hydroxyl, substituted or unsubstituted alkyl, haloalkyl, substituted or unsubstituted alkoxy, haloalkoxy and substituted or unsubstituted cycloalkyl; and ‘n’ is 0, 1, 2, or 3.

7. The compound of claim 1 , wherein R 2 is selected from halogen, hydroxyl, cyano, nitro, substituted or unsubstituted alkyl, haloalkyl, substituted or unsubstituted alkoxy, haloalkoxy and substituted or unsubstituted cycloalkyl.

8. The compound of claim 1 , wherein R 3 is selected from hydrogen, halogen, cyano, hydroxyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy and substituted or unsubstituted cycloalkyl.

9. The compound of claim 1 , wherein one of A and B is N and the other is CH; L is —C(O)NH—, —NHC(O)—or NHCH 2 —; R 1 is same or different and are independently selected from halogen, substituted or unsubstituted alkyl, haloalkyl and substituted or unsubstituted cycloalkyl; ‘n’ is 0, 1, 2, or 3; R 2 is halogen, substituted or unsubstituted alkyl, haloalkyl or substituted or unsubstituted cycloalkyl; R 3 is selected from hydrogen, halogen or substituted or unsubstituted alkyl; and ring E is

10. A compound which is selected from:

2,6-Difluoro-N-(6-(5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-3-yl)benzamide;

2-Fluoro-6-methyl-N-(6-(5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-3-yl)benzamide;

5-(3-Cyclopropyl-1-(5-((2,6-difluorobenzyl)amino)pyridin-2-yl)-1H-pyrazol-5-yl)-3-methyl-1,3,4-oxadiazol-2(3H)-one;

N-(6-(3-(Difluoromethyl)-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,6-difluorobenzamide;

5-(1-(5-((2,6-Difluorobenzyl)amino)pyridin-2-yl)-5-(fluoromethyl)-1H-pyrazol-3-yl)-3-methyl-1,3,4-oxadiazol-2(3H)-one;

2,6-Difluoro-N-(6-(3-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-3-yl)benzamide;

2-Chloro-6-fluoro-N-(6-(3-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-3-yl)benzamide;

2-Fluoro-6-methyl-N-(6-(3-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-3-yl)benzamide;

N-(6-(5-(Difluoromethyl)-3-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,6-difluorobenzamide;

5-(1-(5-((2,6-Difluorobenzyl)amino)pyridin-2-yl)-5-(difluoromethyl)-1H-pyrazol-3-yl)-3-methyl-1,3,4-oxadiazol-2(3H)-one;

5-(1-(5-((2,6-Difluorobenzyl)amino)pyridin-2-yl)-3-(difluoromethyl)-1H-pyrazol-5-yl)-3-methyl-1,3,4-oxadiazol-2(3H)-one;

5-(1-(5-((2,6-Difluorobenzyl)amino)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazol-3-yl)-3-methyl-1,3,4-oxadiazol-2(3H)-one;

5-(1-(5-((2-Chloro-6-fluorobenzyl)amino)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazol-3-yl)-3-methyl- 1,3,4-oxadiazol-2(3H)-one;

N-(6-(5-Cyclopropyl-3-(4-methyl-5-oxo-4,5-dihydro- 1,3,4-oxadiazol-2-yl)- 1H-pyrazol-1-yl)pyridin-3-yl)-2,6-difluorobenzamide;

N-(6-(3-Cyclopropyl-5-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-1H-pyrazol-1-yl)pyridin-3-yl)-2,6-difluorobenzamide;

2,6-Difluoro-N-(6-(5-methyl-3-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-1H-pyrazol-1-yl)pyridin-3-yl)benzamide;

5-(1-(5-((2,6-Difluorobenzyl)amino)pyridin-2-yl)-5-methyl-1H-pyrazol-3-yl)-3-methyl-1,3,4-oxadiazol-2(3H)-one;

2,6-Difluoro-N-(5-(3-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)benzamide;

2-Chloro-6-fluoro-N-(5-(3-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)benzamide;

2-Fluoro-6-methyl-N-(5-(3-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)benzamide;

2-Fluoro-N-(5-(3-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)benzamide;

2,3-Difluoro-N-(5-(3-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)benzamide;

2,4,5-Trifluoro-N-(5-(3-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)benzamide;

2,3,4-Trifluoro-N-(5-(3-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)benzamide;

2,4-Difluoro-N-(5-(3-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)benzamide;

2,3-Dimethyl-N-(5-(3-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)benzamide;

2-Chloro-N-(5-(3-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)benzamide;

2-Methy-N-(5-(3-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)benzamide;

4-Ethyl-N-(5-(3-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)benzamide;

N-(5-(3-(4-Methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-2-yl)-2-naphthamide;

5-(1-(6-((2,6-Difluorobenzyl)amino)pyridin-3-yl)-5-(trifluoromethyl)-1H-pyrazol-3-yl)-3-methyl-1,3,4-oxadiazol-2(3H)-one;

5-(1-(6-((2-Chloro-6-fluorobenzyl)amino)pyridin-3-yl)-5-(trifluoromethyl)-1H-pyrazol-3-yl)-3-methyl-1,3,4-oxadiazol-2(3H)-one;

5-(1-(6-((2-Fluoro-6-methylbenzyl)amino)pyridin-3-yl)-5-(trifluoromethyl)-1H-pyrazol-3-yl)-3-methyl-1,3,4-oxadiazol-2(3H)-one;

N-(2,6-Difluorophenyl)-6-(3-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)nicotinamide and

N-(2-Chloro-6-fluorophenyl)-6-(3-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)nicotinamide

or pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition comprising one or more compounds of Formula (I) according to claim 1 and one or more pharmaceutically acceptable excipients.